Immunovant Share Price Today

Immunovant IMVT-1402 meets primary endpoint in rheumatoid arthritis study

Immunovant's 600 mg IMVT-1402 met the primary endpoint in difficult-to-treat rheumatoid arthritis. The 600 mg cohort achieved a 92.5% ACR20 response rate versus 75.6% for placebo. The 300 mg dose showed no significant difference from placebo with a 75.0% response rate. No serious adverse events or discontinuations due to adverse events were recorded. Shares rose 11.43% to $34.02 following the announcement.

Immunovant files mixed shelf prospectus; terms undisclosed

Immunovant Inc filed a mixed shelf registration statement with the SEC. Specific offering terms, including size and price, remain undisclosed. The filing allows future sales of various securities types.

Immunovant holds $4 billion cash after $950 million Moderna settlement

Cash position stands at nearly $4 billion after receiving $950 million from Moderna settlement. Brepocitinib launch expected by end of September 2026 following priority review. Phase 3 enrollment begun for cutaneous sarcoidosis, targeting 140 patients. Quarterly R&D expenses totaled $200 million; share repurchases reached $200 million.

Kuehn Law probes Immunovant for self-dealing after trial failure

Kuehn Law is investigating Immunovant for potential self-dealing and fiduciary duty breaches. Investigation targets long-term shareholders entitled to damages and governance reforms. Separate probe by Schall, Brown & Schwartz examines securities law violations post-trial failure. IMVT-1402 trial failure on September 23, 2026 caused share price to fall nearly 7.4%.

Immunovant faces securities probe after lupus trial miss sinks stock 6%

Immunovant shares fell roughly 6% on September 23, 2026, to a more-than-three-month low after IMVT-1402 missed its primary endpoint in a cutaneous lupus erythematosus trial. SueWallSt has launched a securities investigation into potential misleading statements regarding IMVT-1402's clinical prospects. Before the disclosure, Immunovant shares traded at approximately $36.95, with a market capitalisation of roughly $7.63 billion. Immunovant will discontinue CLE development and pivot IMVT-1402 to other autoimmune conditions including Graves' disease and myasthenia gravis. Roivant Sciences shares fell 2.93% to $37.10 in premarket trading following the announcement.

Immunovant Q1FY27 Results: $950m Moderna settlement boosts cash

Immunovant received $950 million from Moderna settlement. Cash reserves reached just under $4 billion. R&D expenses totaled $200 million for the quarter. Company repurchased ~$200 million in shares. Brepocitinib launch expected by end of September.